Last reviewed · How we verify
NCT04190121: NEEC
Perioperative Nutritional Support in Esophageal Cancer Patients
NA trial testing prosure in Esophageal Cancer in 110 participants. Status unknown.
14 February 2022
Quick facts
| Lead sponsor | THEODOROU DIMITRIOS |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 110 |
| Start date | 26 March 2019 |
| Primary completion | 14 February 2022 |
| Estimated completion | 14 February 2022 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- prosure
Conditions studied
- Esophageal Cancer — all drugs for Esophageal Cancer →
- Nutritional Deficiency — all drugs for Nutritional Deficiency →
Sponsor
THEODOROU DIMITRIOS
Who can join
18 and older, any sex, with Esophageal Cancer or Nutritional Deficiency. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Upper GI malignancies often lead to involuntary weight loss and nutritional deficits. Nutritional support, both pre- and postoperatively, may improve post-operative course and reduce length of hospital stay. This prospective randomized trial aims to investigate the above mentioned hypothesis and clarify any variants that may differ between the investigation and control group at a statistically significant level.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches.
Cencioni C, Trestini I, Piro G, Bria E, et al · · 2022 · cited 24× · PMID 35458104 · DOI 10.3390/nu14081542
Verify or expand the search:
- PubMed search for NCT04190121
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Cancer
Currently open trials in the same condition.
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
- NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07307560 — High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients · NA · recruiting
Other THEODOROU DIMITRIOS trials
Trials by the same sponsor.
- NCT04288661 — Perianastomotic Drain After Gastrectomy (DRAG) · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04190121 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by THEODOROU DIMITRIOS
- Last refreshed: 9 December 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04190121.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing